Dr PAIN

Dr. PAIN is a clinical-stage biotechnology company based in Tokyo, Japan, specializing in the development of novel analgesics for chronic and neuropathic pain. Spun out from the University of Tokyo, the company focuses on the highly selective inhibition of the voltage-gated sodium channel Nav1.7, a key mediator in pain signaling. Its lead candidate, DPN-001, is a small molecule designed to provide potent pain relief while minimizing the central nervous system and cardiovascular side effects associated with non-selective treatments. By targeting peripheral pain pathways, Dr. PAIN aims to offer a safer alternative to opioids for patients with refractory pain conditions. The company is backed by leading Japanese venture capital firms and continues to leverage its academic roots to advance its pipeline.